Nanoparticle (SpFN) vaccine candidate elicits multifactorial cellular immune responses against SARS-CoV-2 in vivo
Researchers have developed a promising new anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidate that utilizes nanotechnology and shows robust, long-lived immunity in mouse models.
According to this new study, the vaccine enhanced the recruitment of APCs (antigen-presenting cells), increased polyfunctional spike-specific T cells, with a bias towards TH1 responses, IFN-γ and TNFα as the dominant cytokines, and more robust SARS-CoV-2 spike-specific recall response and presented broad protection against other coronavirus strains. The researchers have performed a thorough study of the vaccine-evoked innate and adaptive immune responses in mice against SARS-CoV-2.
United-states
Wuhan
Hubei
China
Epstein-barr
Ramya-dwivedi
Us-army-clinicaltrials
Army-liposome-formulation
Aluminum-hydroxide
ஒன்றுபட்டது-மாநிலங்களில்
சீனா
எப்ஸ்டீன்-பார்